New Horizons in the Treatment of Relapsed/Refractory DLBCL
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 90 Minutes
Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are still characterized by poor outcomes. However, novel therapies have emerged and shown to significantly improve outcomes of these patients. This webcast will review the role of hematopoietic stem cell transplantation, new data and novel therapeutic approaches for the management of R/R DLBCL.
This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.
1. Describe the role of morphology and genetic/molecular imprints in diffuse large B-cell lymphoma (DLBCL)
2. Review new treatment paradigms for relapsed/refractory (R/R) DLBCL
3. Discuss the role of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR) T-cell in the treatment of R/R DLBCL
Marco Ruiz, MD, MPH, MSc, MBA
Dr. Ruiz is a Hematologist Oncologist and Bone Marrow Transplant physician. For over 10 years he has been working with HIV and Geriatric-Oncology patients in the BMT field. He is currently the Co-Director of the Malignant Hematology and BMT Department at Miami Cancer Institute, and Chief of HIV Oncology and HIV BMT. He is the Principal Investigator for the AIDS Malignancy Consortium Clinical Site at Miami Cancer Institute where they offer more than 10 HIV-Oncology clinical trials. He is also the Director of a newly developed Malignant Hematology and Bone Marrow Transplant Fellowship program for mid-level providers at my home institution, Miami Cancer Institute. He also works as an Associate Professor of Clinical Medicine at the Herbert Wertheim College of Medicine, Florida International University. He is the Co-Director of the translational research oncology subdivision. He teaches students, residents and fellows in training.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Marco Ruiz, MD, MPH, MSc, MBA discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
Access to the internet is required.
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above